{"product_id":"from-removing-to-preserving-how-precision-surgery-is-reshaping-head-and-neck-cancer-care","title":"From Removing to Preserving: How Precision Surgery Is Reshaping Head and Neck Cancer Care","description":"\u003cp\u003eHead and neck cancer surgery has changed dramatically over the past 150 years — from radical, disfiguring operations to precise, function-preserving procedures guided by molecular tests and imaging analytics. This comprehensive review reports that comprehensive genomic profiling (full DNA testing of the tumor) finds clinically actionable changes in more than 90% of head and neck squamous cell carcinomas, and that radiomics-based prediction models (computer programs that mine detailed features from scans) reach accuracy above 85% for predicting treatment response. Landmark evidence also shows that multidisciplinary tumor boards can raise five-year disease-specific survival from 52% to 75%, while new surgical technologies such as transoral laser and robotic surgery spare speech and swallowing for many patients. The authors conclude that precision surgery works best when diagnostic biomarkers, imaging prediction models, and perioperative drug therapy are combined — but standardization and prospective survival trials are still needed.\u003c\/p\u003e\n\n\u003ch1\u003eFrom Removing to Preserving: How Precision Surgery Is Reshaping Head and Neck Cancer Care\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#history\"\u003eThe Historical Evolution of Head and Neck Cancer Surgery\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#multidisciplinary\"\u003eMultidisciplinary Care: The Foundation of Modern Treatment\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#teams\"\u003eWho Is on the Modern Treatment Team?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#techniques\"\u003eModern Surgical Techniques and the Evidence Behind Them\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#biomarkers\"\u003eDiagnostic Biomarkers and Radiomics-Based Prediction Models\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Care Teams\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eComprehensive genomic profiling finds clinically actionable changes in over 90% of head and neck squamous cell carcinomas, meaning the finding points to a drug or strategy that could work.\u003c\/li\u003e\n\u003cli\u003eIn one study, five-year disease-specific survival improved from 52% to 75% after multidisciplinary tumor board implementation, though another study found no measurable survival benefit.\u003c\/li\u003e\n\u003cli\u003eTumor board review added about 13 days before treatment started in one study, and established evidence links treatment delays to tumor progression and clinical upstaging.\u003c\/li\u003e\n\u003cli\u003eFor selected early and intermediate-risk tumors, transoral laser and robotic surgery can spare speech and swallowing; a trial reported 95% aspiration-free swallowing at 12 months.\u003c\/li\u003e\n\u003cli\u003eRadiomics models reach accuracy above 85% for predicting treatment response when validated across independent cohorts, but standardization and prospective survival trials are still needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eHead and neck cancer is a major global health problem. Each year, more than \u003cstrong\u003e900,000 new cases\u003c\/strong\u003e are diagnosed worldwide, and approximately \u003cstrong\u003e460,000 people die\u003c\/strong\u003e from the disease. These tumors rank among the most common cancers globally.\u003c\/p\u003e\n\n\u003cp\u003eWhat makes head and neck cancer uniquely challenging is its location. These cancers grow in anatomical regions critical for \u003cstrong\u003espeech, swallowing, breathing, and facial appearance\u003c\/strong\u003e. A cure that destroys these functions can still devastate a patient's quality of life.\u003c\/p\u003e\n\n\u003cp\u003eThis review concentrates on cancers of the \u003cstrong\u003eoral cavity (mouth), oropharynx (the middle part of the throat behind the mouth), and larynx (voice box)\u003c\/strong\u003e. In these sites, \u003cstrong\u003esquamous cell carcinoma (SCC)\u003c\/strong\u003e — a cancer arising from the flat, scale-like cells lining these surfaces — accounts for over \u003cstrong\u003e90% of cases\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eContemporary diagnosis relies on advanced imaging. \u003cstrong\u003eMagnetic resonance imaging (MRI)\u003c\/strong\u003e gives the best detail of soft tissue. \u003cstrong\u003ePositron emission tomography combined with computed tomography (PET\/CT)\u003c\/strong\u003e assesses tumor metabolism and lymph node spread. An integrated \u003cstrong\u003ePET\/MRI\u003c\/strong\u003e combines anatomical detail with functional information. Recent high-quality meta-analyses (studies that pool results from many trials) have validated the diagnostic accuracy of all three.\u003c\/p\u003e\n\n\u003cp\u003eTwo developments in the past two decades transformed the field. First, researchers identified \u003cstrong\u003ehuman papillomavirus (HPV)\u003c\/strong\u003e as a cause of oropharyngeal cancer — a biologically distinct disease with a better prognosis than HPV-negative tumors. Second, \u003cstrong\u003eimmunotherapy\u003c\/strong\u003e (treatment that helps the immune system attack cancer) emerged, with \u003cstrong\u003ePD-1\/PD-L1 expression\u003c\/strong\u003e (proteins that cancer cells use to hide from the immune system) serving as validated predictive biomarkers.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Review Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis is a comprehensive literature review, not a single clinical trial. The authors focused on studies published in the \u003cstrong\u003epast five years\u003c\/strong\u003e, while incorporating relevant publications from the \u003cstrong\u003elast three decades\u003c\/strong\u003e and landmark historical papers.\u003c\/p\u003e\n\n\u003cp\u003eThe paper was written by members and invitees of the \u003cstrong\u003eInternational Head and Neck Scientific Group\u003c\/strong\u003e based in Padua, Italy. The authors examined the evolving role of surgery and placed special emphasis on diagnostic methodologies, including comprehensive genomic profiling and validated imaging biomarkers.\u003c\/p\u003e\n\n\u003cp\u003eThe review also assessed how these tools integrate into clinical practice for treatment selection and response prediction. In other words, the authors asked not just \"does the test work?\" but \"does using it change what we do for patients?\"\u003c\/p\u003e\n\n\u003ch2 id=\"history\"\u003eThe Historical Evolution of Head and Neck Cancer Surgery\u003c\/h2\u003e\n\n\u003ch3\u003eThe Era of Radical Surgery (19th Century to the 1970s)\u003c\/h3\u003e\n\n\u003cp\u003eThe foundational era was defined by radical open resections with wide margins. Surgeons accepted major functional loss as the price of cancer control. Theodore Billroth pioneered this approach, performing the \u003cstrong\u003efirst laryngectomy in Vienna in 1873\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eOn \u003cstrong\u003eJanuary 17, 1888\u003c\/strong\u003e, Polish surgeon \u003cstrong\u003eFranciszek Jawdyński (1851–1896)\u003c\/strong\u003e performed a successful radical en bloc neck dissection. \"En bloc\" means removing the entire tumor and surrounding tissue in one intact piece. He published a detailed description in the Polish journal \u003cem\u003eGazeta Lekarska\u003c\/em\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHis procedure incorporated all elements of modern neck dissection. He removed the lymphoareolar contents (lymph nodes and surrounding fatty tissue) from the jawbone to the collarbone, including the \u003cstrong\u003esternocleidomastoid muscle\u003c\/strong\u003e (the large muscle on the side of the neck). He tied off the \u003cstrong\u003einternal jugular vein\u003c\/strong\u003e (the major vein draining blood from the head) both below and above, and included it in the removed specimen.\u003c\/p\u003e\n\n\u003cp\u003eRemarkably, the patient tolerated the ligation of the carotid artery and survived \u003cstrong\u003eseven years\u003c\/strong\u003e, apparently free of disease.\u003c\/p\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e1905\u003c\/strong\u003e, \u003cstrong\u003eGeorge Washington Crile (1864–1943)\u003c\/strong\u003e of Cleveland, Ohio, presented a report titled \"On the Surgical Treatment of Cancer of the Head and Neck,\" summarizing \u003cstrong\u003e121 operations performed on 105 patients\u003c\/strong\u003e. In \u003cstrong\u003eJune 1906\u003c\/strong\u003e, he presented similar material based on \u003cstrong\u003e132 operations\u003c\/strong\u003e at the 57th annual meeting of the American Medical Association. This paper, published in the \u003cem\u003eJournal of the American Medical Association\u003c\/em\u003e, had widespread impact and revolutionized head and neck cancer treatment.\u003c\/p\u003e\n\n\u003cp\u003eLater, the Memorial Hospital approach under \u003cstrong\u003eHayes Martin\u003c\/strong\u003e became the international standard. His \"Commando operation\" for advanced oral cancers represented the peak of radical surgical philosophy. However, the substantial illness burden and functional deficits from these operations pushed researchers to seek alternatives.\u003c\/p\u003e\n\n\u003ch3\u003eThe Organ Preservation Movement (1980s to 2000s)\u003c\/h3\u003e\n\n\u003cp\u003eFunctional and cosmetic harm from radical surgery — combined with the recognized effectiveness of \u003cstrong\u003ecisplatin-based chemotherapy\u003c\/strong\u003e (a platinum-based drug regimen) — triggered the organ preservation movement.\u003c\/p\u003e\n\n\u003cp\u003eThe landmark \u003cstrong\u003eVeterans Affairs laryngeal preservation trial\u003c\/strong\u003e was a pivotal moment. It showed that organ preservation could be achieved without compromising survival in carefully selected patients. Importantly, these patients were treated by experienced multidisciplinary teams that provided balanced case assessment, therapeutic expertise, follow-up, and timely surgical salvage.\u003c\/p\u003e\n\n\u003cp\u003eBuilding on that foundation, the \u003cstrong\u003eRTOG 91-11 trial\u003c\/strong\u003e showed superior laryngeal preservation rates when \u003cstrong\u003ecisplatin and radiation were given concurrently\u003c\/strong\u003e (at the same time) compared with induction chemotherapy. Both sequential and concurrent approaches produced longer laryngectomy-free survival, with the highest organ preservation rates in the concurrent arm.\u003c\/p\u003e\n\n\u003cp\u003eThis era also brought medical oncology permanently into head and neck cancer care, establishing the foundation for modern multidisciplinary management.\u003c\/p\u003e\n\n\u003ch3\u003eThe Era of Minimally Invasive Precision Surgery (2000s to Present)\u003c\/h3\u003e\n\n\u003cp\u003eAdvances in \u003cstrong\u003eCO₂ laser technology\u003c\/strong\u003e (carbon dioxide laser), endoscopic optics, robotic manipulation, systemic therapy, and radiotherapy enabled \u003cstrong\u003etransoral resections\u003c\/strong\u003e — surgery performed through the mouth rather than through an incision in the neck. For selected upper aerodigestive tumors (cancers of the upper airway and food passage), these approaches achieved the same locoregional control.\u003c\/p\u003e\n\n\u003cp\u003eAt the same time, standardized multidisciplinary tumor boards and perioperative collaboration became routine. Most significantly, researchers are now intensively studying how to integrate validated diagnostic biomarkers with neoadjuvant immunotherapy and chemotherapy. \"Neoadjuvant\" means treatment given before the main treatment. The goal is \u003cstrong\u003eresponse-adaptive therapy\u003c\/strong\u003e — adjusting treatment based on how well the tumor responds.\u003c\/p\u003e\n\n\u003ch2 id=\"multidisciplinary\"\u003eMultidisciplinary Care: The Foundation of Modern Treatment\u003c\/h2\u003e\n\n\u003cp\u003eMultidisciplinary care means coordinated team-based management. Specialists evaluate patients together, develop an integrated treatment plan, and deliver synchronized care rather than working in isolation.\u003c\/p\u003e\n\n\u003cp\u003eBefore any treatment plan begins, \u003cstrong\u003ehistopathological confirmation through biopsy is mandatory\u003c\/strong\u003e — a tissue sample must confirm the cancer under a microscope. Doctors then combine clinical examination with advanced imaging to assess disease extent and assign an accurate stage.\u003c\/p\u003e\n\n\u003cp\u003eStaging follows the \u003cstrong\u003eTumor-Node-Metastasis (TNM) system\u003c\/strong\u003e established by the \u003cstrong\u003eUnion for International Cancer Control (UICC)\u003c\/strong\u003e and the \u003cstrong\u003eAmerican Joint Committee on Cancer (AJCC)\u003c\/strong\u003e, currently in its \u003cstrong\u003eeighth edition\u003c\/strong\u003e. This standard framework provides essential prognostic information and guides treatment decisions.\u003c\/p\u003e\n\n\u003cp\u003eComprehensive preoperative evaluation integrates clinical, biochemical, and imaging assessments. Clinical evaluation covers tumor examination, cervical lymph node assessment, cranial nerve function, and \u003cstrong\u003eairway patency\u003c\/strong\u003e (whether the breathing passage is open).\u003c\/p\u003e\n\n\u003cp\u003eBiochemical workup includes complete blood count, kidney and liver function, coagulation profile, and nutritional markers. Cross-sectional imaging with CT or MRI defines tumor extent and whether it can be surgically removed. PET\/CT detects distant metastases and characterizes nodal disease. Cardiopulmonary assessment confirms the patient has enough physiologic reserve for major surgery.\u003c\/p\u003e\n\n\u003ch3\u003eEvidence-Based Benefits of Integrated Care Models\u003c\/h3\u003e\n\n\u003cp\u003eThe evidence for multidisciplinary tumor boards (MTBs) is strong but nuanced. \u003cstrong\u003eLiu et al.\u003c\/strong\u003e demonstrated survival benefits after MTB implementation. Five-year disease-specific survival improved from \u003cstrong\u003e52% to 75%\u003c\/strong\u003e (p=0.003) — a 23 percentage-point gain, or roughly 23 more patients surviving out of every 100. Overall survival rose from \u003cstrong\u003e40% to 61%\u003c\/strong\u003e (p=0.008).\u003c\/p\u003e\n\n\u003cp\u003eThese improvements held even after researchers controlled for stage and other confounding variables. Structured multidisciplinary evaluation improved coordination between specialties.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBurkhardt et al.\u003c\/strong\u003e showed in a retrospective study that pretherapeutic MTB evaluation significantly improved adherence to evidence-based clinical guidelines. Compliance rates reached \u003cstrong\u003e79.6% versus 68%\u003c\/strong\u003e in non-MTB cohorts (p\u0026lt;0.01) — about 12 more patients in every 100 receiving guideline-concordant care.\u003c\/p\u003e\n\n\u003cp\u003eThe improvement was especially visible in neck dissection procedures. MTB-reviewed cases showed substantially higher rates of comprehensive surgical intervention: \u003cstrong\u003e90.5% versus 78.9%\u003c\/strong\u003e (p\u0026lt;0.001).\u003c\/p\u003e\n\n\u003cp\u003eHowever, these benefits come with notable limitations. MTB presentation introduced statistically significant delays in starting treatment. The mean delay was approximately \u003cstrong\u003e13 days\u003c\/strong\u003e longer (\u003cstrong\u003e33.5 versus 20.1 days\u003c\/strong\u003e, p\u0026lt;0.001). This delay appeared consistently across all UICC stages.\u003c\/p\u003e\n\n\u003cp\u003eThat delay matters. Established evidence links treatment delays to tumor progression and clinical upstaging. Perhaps most striking, this particular study found \u003cstrong\u003eno measurable survival benefit\u003c\/strong\u003e — no significant differences in three-year survival, disease-free survival, or five-year survival between MTB and non-MTB cohorts. Enhanced guideline adherence did not necessarily translate into better cancer outcomes for oral cavity cancer patients in that analysis.\u003c\/p\u003e\n\n\u003cp\u003eA much larger study addressed this question. The \u003cstrong\u003eWiZen (Effectiveness of Care in Certified Cancer Centers)\u003c\/strong\u003e study in Germany analyzed nationwide data from approximately \u003cstrong\u003e22 million adult statutory health insurance beneficiaries\u003c\/strong\u003e between \u003cstrong\u003e2009 and 2017\u003c\/strong\u003e, covering \u003cstrong\u003e11 cancer types\u003c\/strong\u003e, including head and neck cancer.\u003c\/p\u003e\n\n\u003cp\u003eFor head and neck malignancies, \u003cstrong\u003e8,173 patients\u003c\/strong\u003e received initial treatment in German Cancer Society (DKG)-certified centers, compared with \u003cstrong\u003e44,576\u003c\/strong\u003e in non-certified institutions. Certified centers mandate both preoperative and postoperative MTB evaluation.\u003c\/p\u003e\n\n\u003cp\u003eInitial treatment in certified centers was associated with improved overall survival across all examined cancer types. For head and neck cancer, the adjusted \u003cstrong\u003ehazard ratio was 0.94 (95% CI: 0.89–1.00, p=0.038)\u003c\/strong\u003e. A hazard ratio below 1.0 means lower risk of death over time. This corresponded to an absolute risk reduction of \u003cstrong\u003e1.79 months\u003c\/strong\u003e of survival.\u003c\/p\u003e\n\n\u003cp\u003eThe advantage remained consistent after extensive adjustment for patient-level factors (age, sex, distant metastases, other illnesses) and hospital-level variables (bed capacity, university status, ownership). Sensitivity analyses revealed the benefit tended to strengthen with longer duration of certification. This suggests cumulative effects from sustained use of evidence-based protocols.\u003c\/p\u003e\n\n\u003cp\u003eMechanisms behind MTB benefits extend beyond treatment selection. Adding speech-language pathology, nutrition, palliative care, and social work services to the MTB framework produced tangible functional improvements. Pretreatment gastrostomy rates (surgical placement of a feeding tube) fell in advanced disease patients: \u003cstrong\u003e39% versus 26%\u003c\/strong\u003e (p=0.03). Patients also reported improved quality of life and more dignified end-of-life care.\u003c\/p\u003e\n\n\u003ch2 id=\"teams\"\u003eWho Is on the Modern Treatment Team?\u003c\/h2\u003e\n\n\u003cp\u003eModern treatment teams typically include surgical oncologists, radiation oncologists, medical oncologists, pathologists, radiologists, speech-language pathologists, nutritionists, palliative care specialists, and psychosocial support specialists. Each contributes specialized expertise toward unified, patient-centered goals.\u003c\/p\u003e\n\n\u003cp\u003eWithin this framework, the surgeon's role has evolved well beyond performing operations. It now includes initial diagnosis and staging, treatment selection, pretreatment support, assessment during chemoradiation, post-treatment evaluation, salvage surgery, and management of late side effects.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, institutions with well-established multidisciplinary teams remain limited. The authors note that the lack of this organizational structure for most patients seeking therapy represents a major obstacle to accessing adequate care.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eTeam Member\u003c\/th\u003e\n\u003cth\u003ePrimary Responsibilities\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHead and Neck Surgical Oncologist\u003c\/td\u003e\n\u003ctd\u003eSurgical candidacy determination; timing coordination; tumor resection and neck dissection; reconstruction planning (with plastic surgeon); surgical complication management\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiation Oncologist\u003c\/td\u003e\n\u003ctd\u003eRadiation therapy design and delivery; dose determination; adjuvant (post-surgery) and definitive protocols; radiation toxicity management\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Oncologist\u003c\/td\u003e\n\u003ctd\u003eSystemic chemotherapy, targeted therapy and immunotherapy; perioperative therapy; clinical trial enrollment; systemic treatment toxicity management\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePathologist\u003c\/td\u003e\n\u003ctd\u003eDiagnosis including molecular analysis; margin and lymph node assessment; biomarker testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiologist\u003c\/td\u003e\n\u003ctd\u003eDiagnostic imaging interpretation; radiomics analysis; resectability assessment; response evaluation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpeech-Language Pathologist\u003c\/td\u003e\n\u003ctd\u003eSwallowing and speech assessment and management; rehabilitation therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutritionist\u003c\/td\u003e\n\u003ctd\u003eNutritional status evaluation; feeding support coordination; management of nutrition-related treatment complications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePalliative Care Specialist\u003c\/td\u003e\n\u003ctd\u003ePain and symptom control; psychosocial support; goals-of-care discussions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSocial Worker\u003c\/td\u003e\n\u003ctd\u003eCare coordination; psychosocial barrier management; resource connection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNurse Navigator\u003c\/td\u003e\n\u003ctd\u003ePrimary contact; patient and family education; appointment coordination; treatment monitoring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2 id=\"techniques\"\u003eModern Surgical Techniques and the Evidence Behind Them\u003c\/h2\u003e\n\n\u003ch3\u003eTransoral Laser Microsurgery: Precision Through Technology\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003eTransoral laser microsurgery (TLM)\u003c\/strong\u003e has been a standard technique for the past three decades. It uses precise CO₂ laser technology combined with operative microscopy or exoscopy (a minimally invasive visualization technique) to remove tumors accurately with excellent control of bleeding.\u003c\/p\u003e\n\n\u003cp\u003eTechnological advances include micromanipulators that focus the laser beam precisely, pulsed laser systems that reduce thermal damage to tissue, and specialized surgical laryngoscopes and microinstruments. Standardized methods for processing the removed tissue under the microscope further improved oncologic precision.\u003c\/p\u003e\n\n\u003cp\u003ePerioperative complications of TLM are low. A tracheostomy (surgical opening in the windpipe) can be avoided in most cases. Functional outcomes are significantly better than open surgery, because surgeons avoid cutting through the neck and preserve more healthy surrounding tissue.\u003c\/p\u003e\n\n\u003cp\u003eA prospective multicenter trial of TLM for supraglottic carcinoma (cancer of the upper part of the voice box) reported \u003cstrong\u003e95% aspiration-free swallowing at 12 months\u003c\/strong\u003e. Aspiration means food or liquid entering the airway. Importantly, there was \u003cstrong\u003eno long-lasting impact on voice- or swallowing-related quality of life\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eTLM is now widely accepted for early laryngeal and selected oropharyngeal cancers. With adequate surgical experience, TLM can replace open partial laryngectomy. In selected cases where tumors are reachable endoscopically and removable with function preserved, cancers of the oral cavity, oropharynx, and hypopharynx can also be resected this way. Combining TLM with selective neck dissection and adjuvant radiation achieves favorable oncologic and functional results.\u003c\/p\u003e\n\n\u003ch3\u003eTransoral Robotic Surgery: Guidelines and Expanding Applications\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003eTransoral robotic surgery (TORS)\u003c\/strong\u003e has revolutionized surgical access to the oropharynx and supraglottic larynx. A multi-institutional randomized clinical trial showed that primary transoral surgery with reduced postoperative radiation improves oncologic and functional outcomes in \u003cstrong\u003eintermediate-risk HPV-positive oropharyngeal cancer\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eRecent comprehensive guidelines from the \u003cstrong\u003eAmerican Society of Clinical Oncology (ASCO)\u003c\/strong\u003e establish evidence-based recommendations for TORS in multidisciplinary care. The robotic platform gives surgeons three-dimensional endoscopic visualization, wristed instruments with \u003cstrong\u003eseven degrees of freedom\u003c\/strong\u003e, tremor filtration, and motion scaling — all of which significantly enhance surgical precision.\u003c\/p\u003e\n\n\u003cp\u003eNewer single-port robotic systems promise to reduce invasiveness further while maintaining precision. A prospective multicenter phase 2 clinical trial evaluated a next-generation single-port robotic system for TORS in \u003cstrong\u003e47 patients\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe results were encouraging:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAll patients safely underwent transoral resection \u003cstrong\u003ewithout conversion to open surgery\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNo intraoperative complications\u003c\/strong\u003e occurred\u003c\/li\u003e\n\u003cli\u003eMean estimated blood loss was only \u003cstrong\u003e15.4 mL\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe single-port architecture uses three fully articulating 6-mm instruments and a flexible stereoendoscopic camera, all deployed through a compact \u003cstrong\u003e25-mm port\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRadical Surgical Approaches: Contemporary Indications\u003c\/h3\u003e\n\n\u003cp\u003eRadical surgery still plays an essential role for advanced malignancies where tumor extent rules out function-preserving approaches. \u003cstrong\u003eTotal laryngectomy\u003c\/strong\u003e addresses advanced laryngeal cancers with extensive cartilage invasion. It creates a permanent tracheostoma (a surgical opening in the neck for breathing), but it also enables \u003cstrong\u003etracheoesophageal voice rehabilitation\u003c\/strong\u003e (voice restored using a small valve between the windpipe and food pipe).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eComposite resections\u003c\/strong\u003e combine mandibulectomy (removal of part of the jawbone) with soft tissue removal for bone-invasive tumors. These require \u003cstrong\u003efibular free flap reconstruction\u003c\/strong\u003e — using a piece of the leg bone to rebuild the jaw — to restore facial contour and chewing function.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMaxillectomy\u003c\/strong\u003e procedures address sinonasal malignancies. Prosthodontic rehabilitation through obturator placement (a removable prosthesis that closes the surgical opening) enables functional restoration.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRadical neck dissection\u003c\/strong\u003e removes all lymphatic levels and sacrifices the sternocleidomastoid muscle, internal jugular vein, and spinal accessory nerve. It remains indicated for extensive nodal disease with extranodal extension, meaning cancer has broken out of the lymph node capsule. These procedures require extensive preoperative counseling about functional losses.\u003c\/p\u003e\n\n\u003ch2 id=\"biomarkers\"\u003eDiagnostic Biomarkers and Radiomics-Based Prediction Models\u003c\/h2\u003e\n\n\u003cp\u003eThe review's central message is that modern surgery is becoming data-driven. Several specific diagnostic technologies now guide treatment selection.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComprehensive genomic profiling\u003c\/strong\u003e (full DNA analysis of the tumor) identifies clinically actionable alterations in \u003cstrong\u003eover 90% of head and neck squamous cell carcinomas\u003c\/strong\u003e. \"Actionable\" means the finding points to a drug or strategy that could work.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTumor mutational burden (TMB)\u003c\/strong\u003e — the total number of mutations in a tumor's DNA — serves as a validated predictive biomarker for immunotherapy response.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProgrammed death-ligand 1 (PD-L1) combined positive score\u003c\/strong\u003e — a laboratory measure of how much of this immune-hiding protein the tumor and surrounding cells carry — functions as a validated diagnostic biomarker for immunotherapy efficacy. It shows significant clinical benefit in biomarker-selected populations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRadiomics-based predictive models\u003c\/strong\u003e using machine learning algorithms achieve diagnostic accuracies \u003cstrong\u003eexceeding 85%\u003c\/strong\u003e for treatment response prediction when validated across independent cohorts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQuantitative ultrasound spectroscopy\u003c\/strong\u003e combined with \u003cstrong\u003eMRI radiomics\u003c\/strong\u003e demonstrates high sensitivity and specificity for predicting radiation response.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHabitat imaging\u003c\/strong\u003e — techniques that map different regions within a single tumor based on the microenvironment — predicts \u003cstrong\u003epathologic complete response\u003c\/strong\u003e (no cancer cells left in the removed tissue) to neoadjuvant chemoimmunotherapy, with \u003cstrong\u003earea under the curve (AUC) values approaching 0.90\u003c\/strong\u003e in validation studies. An AUC near 0.90 indicates excellent ability to tell responders from non-responders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTogether, these methods enable \u003cstrong\u003eresponse-adaptive treatment strategies\u003c\/strong\u003e. The review reports that neoadjuvant chemotherapy facilitates \u003cstrong\u003emandibular preservation\u003c\/strong\u003e (avoiding jaw removal) and permits \u003cstrong\u003eadjuvant therapy omission\u003c\/strong\u003e (skipping post-surgery treatment) in \u003cstrong\u003eover half of HPV-associated cases\u003c\/strong\u003e following surgical downstaging. Downstaging means the tumor shrank before surgery.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eClinical validation of these diagnostic platforms enables accurate treatment response prediction and informed surgical decision-making. In practical terms, patients may face fewer \"one-size-fits-all\" decisions.\u003c\/p\u003e\n\n\u003cp\u003eFor a patient with HPV-positive oropharyngeal cancer, biomarker and imaging data may help the team decide whether surgery alone followed by reduced radiation is enough. For a patient with advanced laryngeal cancer, a multidisciplinary team can weigh organ preservation against total laryngectomy using evidence, not guesswork.\u003c\/p\u003e\n\n\u003cp\u003eThe authors emphasize a paradigm shift. Surgery once stood alone, focused solely on cancer control. It is now one component of carefully coordinated treatment that prioritizes both cure and function, according to patient preferences.\u003c\/p\u003e\n\n\u003cp\u003eThe review also notes that organ preservation strategies achieve equivalent survival outcomes while maintaining physiologic function in appropriately selected patients. Selection is the key word — not every patient qualifies.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eThis is a literature review, not a prospective randomized trial, so it cannot establish cause and effect on its own. Several specific gaps remain.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStandardization across institutions is lacking.\u003c\/strong\u003e The authors state that standardization of these diagnostic platforms remains essential for broader implementation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSurvival benefit is unproven for many approaches.\u003c\/strong\u003e Demonstration of survival benefits through prospective trials is still required.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe multidisciplinary board evidence is mixed.\u003c\/strong\u003e One study found no measurable survival benefit despite better guideline adherence, and MTB review added about 13 days of delay.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess is unequal.\u003c\/strong\u003e Institutions with well-established multidisciplinary teams remain limited, and most patients seeking therapy lack this organizational structure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMuch radiomics and biomarker evidence comes from validation studies\u003c\/strong\u003e rather than large randomized trials with long-term follow-up.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Care Teams\u003c\/h2\u003e\n\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsk whether your case has been reviewed by a multidisciplinary tumor board.\u003c\/strong\u003e Review is associated with better guideline adherence and, in large certified-center data, a modest survival advantage (hazard ratio 0.94).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRequest biomarker testing on your tumor tissue.\u003c\/strong\u003e Comprehensive genomic profiling finds actionable changes in over 90% of head and neck squamous cell carcinomas. TMB and PD-L1 testing can guide immunotherapy decisions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsk about function-preserving options.\u003c\/strong\u003e Transoral laser microsurgery and robotic surgery can spare speech and swallowing in appropriately selected early and intermediate-risk tumors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiscuss treatment timing.\u003c\/strong\u003e Multidisciplinary review may add roughly 13 days before treatment starts. Ask your team how they balance thorough planning against delay.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRequest access to supportive services.\u003c\/strong\u003e Including speech-language pathology, nutrition, and palliative care reduced pretreatment feeding tube placement (26% versus 39%) in advanced disease.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials.\u003c\/strong\u003e The authors state that prospective trials are still needed to prove survival benefits from precision surgery and biomarker-driven care.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is comprehensive genomic profiling and what can it find?\u003c\/h3\u003e\n\u003cp\u003eIt is full DNA analysis of your tumor. In head and neck squamous cell carcinoma, it identifies clinically actionable changes in more than 90% of cases. Actionable means the finding points to a drug or strategy that could work. Ask your team whether your tumor tissue has had this testing.\u003c\/p\u003e\n\u003ch3\u003eWhat is a multidisciplinary tumor board and should my case go to one?\u003c\/h3\u003e\n\u003cp\u003eIt is a coordinated team of specialists who review your case together and plan treatment. One study found five-year disease-specific survival rose from 52% to 75% after tumor board implementation. Ask whether your case has been reviewed by one, and how your team balances thorough planning against delay.\u003c\/p\u003e\n\u003ch3\u003eDoes multidisciplinary review delay treatment, and does that matter?\u003c\/h3\u003e\n\u003cp\u003eIn one study, tumor board presentation added about 13 days before treatment started (33.5 versus 20.1 days). That delay appeared across all UICC stages. Established evidence links treatment delays to tumor progression and clinical upstaging. Ask your team how they weigh thorough planning against this delay.\u003c\/p\u003e\n\u003ch3\u003eCan surgery preserve my speech and swallowing?\u003c\/h3\u003e\n\u003cp\u003eFor appropriately selected early and intermediate-risk tumors, transoral laser microsurgery and transoral robotic surgery can spare speech and swallowing. A prospective multicenter trial of laser microsurgery for supraglottic carcinoma reported 95% aspiration-free swallowing at 12 months, with no long-lasting impact on voice- or swallowing-related quality of life. Not every patient qualifies.\u003c\/p\u003e\n\u003ch3\u003eWhat does an accuracy above 85% mean for radiomics prediction models?\u003c\/h3\u003e\n\u003cp\u003eRadiomics uses computer programs that mine detailed features from scans. When validated across independent cohorts, these models reach diagnostic accuracies above 85% for predicting treatment response. That means they correctly identify responders versus non-responders in most, but not all, cases. Ask how such results would change your own treatment plan.\u003c\/p\u003e\n\u003ch3\u003eWhat supportive services can be added to my care team?\u003c\/h3\u003e\n\u003cp\u003eTeams may include speech-language pathologists, nutritionists, palliative care specialists, and social workers. Adding these services to the tumor board framework reduced pretreatment feeding tube placement in advanced disease patients: 39% versus 26%. Patients also reported improved quality of life and more dignified end-of-life care. Ask about access to these services.\u003c\/p\u003e\n\u003ch3\u003eAre survival benefits from precision surgery proven?\u003c\/h3\u003e\n\u003cp\u003eNot yet for many approaches. The review states that demonstration of survival benefits through prospective trials is still required. One tumor board study found no measurable survival benefit despite better guideline adherence. A large German study of 8,173 head and neck patients treated in certified centers found a modest overall survival advantage (hazard ratio 0.94). Ask about clinical trials.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with head and neck cancer seek a second opinion before surgery?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth considering when the recommended operation could remove the voice box, jaw, or other structures needed for speech and swallowing, since transoral laser and robotic surgery can preserve these functions in appropriately selected early and intermediate-risk tumors. It also helps when biomarker testing has not been discussed, because comprehensive genomic profiling identifies actionable changes in over 90% of head and neck squamous cell carcinomas, and when it is unclear whether a multidisciplinary tumor board has reviewed the case. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e From Radical Resection to Precision Surgery: Integrating Diagnostic Biomarkers, Radiomics-Based Predictive Models, and Perioperative Systemic Therapy in Head and Neck Oncology.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Kowalski LP, Bradford CR, Beitler JJ, Rodrigo JP, Guntinas-Lichius O, Ambrosch P, Forastiere AA, Rao KN, Hamoir M, Saba NF, Sanabria A, Strojan P, Robbins KT, Ferlito A.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e \u003cem\u003eDiagnostics\u003c\/em\u003e 2026, volume 16, article 49. Published 23 December 2025. Received 21 October 2025; revised 3 December 2025; accepted 9 December 2025. Open access under a Creative Commons Attribution (CC BY) license.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47738998423708,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/from-removing-to-preserving-how-precision-surgery-is-reshaping-head-and-neck-cancer-care","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}